Nanoparticles in Vaccines
Nanoparticles in Vaccines refers to the use of engineered nanoscale materials as delivery vehicles, adjuvants, or stabilising agents within vaccine formulations. While the use of Lipid Nanoparticles (LNPs) as mRNA delivery systems in COVID Vaccines is extensively documented and publicly acknowledged, a growing body of independent research has raised questions about additional undisclosed nanomaterials potentially present in certain vaccine batches. This page surveys the documented science, the regulatory framework, independent research methodologies, and the implications for Bodily Autonomy and informed consent.
Lipid Nanoparticles: The Documented Delivery Mechanism
Lipid nanoparticles are the core nanotechnology platform used in the Pfizer-BioNTech (Comirnaty) and Moderna (Spikevax) COVID-19 vaccines. These are synthetic fatty-acid shells, typically 80–120 nanometres in diameter, designed to encapsulate fragile mRNA strands and facilitate their entry into human cells.
The four lipid components in the Pfizer vaccine include:
- ALC-0315 – a novel ionisable cationic lipid, the primary functional component enabling endosomal escape
- ALC-0159 – a PEGylated lipid (polyethylene glycol), used to extend circulation time and reduce immune recognition
- DSPC – a phospholipid providing structural stability
- Cholesterol – a naturally occurring lipid aiding membrane fusion
The Moderna vaccine uses slightly different ionisable lipids (SM-102) alongside similar PEG and structural lipids. ALC-0315 and SM-102 were novel compounds with limited prior human safety data at the time of emergency use authorisation. Some toxicologists have noted that ionisable cationic lipids have known cytotoxic properties at higher concentrations, and that their biodistribution — originally assumed to remain local at the injection site — was later shown in a Japanese regulatory document to distribute to multiple organs including the ovaries, liver, and adrenal glands.
Regulatory Disclosure: What Was and Was Not Required
FDA Approval Process
The FDA granted Emergency Use Authorisation (EUA) to COVID-19 mRNA vaccines in December 2020, followed by full Biologics License Application (BLA) approval for Comirnaty in August 2021. The EUA pathway requires demonstration of safety and efficacy based on available data but does not mandate the same depth of long-term safety studies required under the standard approval process.
Crucially for nanotechnology:
- The FDA's existing regulatory framework for nanomaterials in drugs is primarily governed by guidance documents rather than binding regulation. The agency published a non-binding guidance on nanotechnology in 2014, updated in 2022, but this does not constitute mandatory testing protocol.
- Manufacturers were required to characterise the particle size distribution, encapsulation efficiency, and general physicochemical properties of the LNPs.
- No specific requirement existed to screen for or disclose non-lipid nanomaterial contaminants, as the assumption was that manufacturing standards (Good Manufacturing Practice, GMP) would preclude contamination.
EMA Approval Process
The EMA (European Medicines Agency) authorised the Pfizer and Moderna vaccines under a Conditional Marketing Authorisation in December 2020. The EMA's assessment report for Comirnaty, running to several hundred pages, includes detailed characterisation of the LNP system. However, critics have noted:
- The assessment acknowledges that ALC-0315 had not previously been used in an approved medicine, with no pre-existing human safety database.
- Genotoxicity studies for ALC-0315 were conducted on a shortened timeline.
- The EMA's own documentation flagged the lack of long-term immunogenicity data as an outstanding issue to be resolved post-authorisation.
Independent analysts and MEPs in the European Parliament have subsequently questioned whether the full manufacturing data submitted to the EMA should be made public, citing concerns about the completeness of ingredient disclosure.
Independent Research: Findings on Undisclosed Nanomaterials
Starting in mid-2021 and continuing through 2023, a number of independent researchers — working outside pharmaceutical industry funding — undertook their own microscopic and spectroscopic analyses of COVID vaccine contents. Their findings have been controversial, disputed by mainstream bodies, and largely ignored by regulatory agencies, but the methodologies used are standard analytical chemistry techniques.
Carbon Quantum Dots and Graphene Quantum Dot Structures
One of the more specific claims to emerge from independent analysis concerns the alleged presence of Carbon Quantum Dot (CQD) and graphene quantum dot (GQD) structures within COVID-19 vaccine samples. Quantum dots are nanoscale semiconductor or carbon-lattice particles — typically 2–10 nanometres in diameter — that exhibit unique optical and electronic properties due to quantum confinement effects.
La Quinta Columna, a Spanish research group whose findings were first publicised in 2021, and the associated analytical blog Corona2Inspect, have alleged the detection of structures consistent with graphene quantum dots and carbon dot formations in multiple COVID-19 vaccine preparations. Their evidence citations include:
- Electron microscopy images purportedly showing hexagonal lattice nanostructures at the sub-10-nanometre scale, consistent with graphene-family quantum dot morphology
- Raman spectroscopy readings exhibiting the characteristic D, G, and 2D band signatures associated with sp² carbon networks, alongside fluorescence emission profiles consistent with quantum dot photoluminescence
- Cross-referencing with published peer-reviewed literature on the synthesis and properties of graphene quantum dots, arguing the spectral signatures are a close match
According to these researchers, if graphene quantum dots are present in vaccine preparations, their significance would extend beyond simple contamination. Published scientific literature — including studies in ACS Nano, Advanced Materials, and Carbon — has established that carbon quantum dots and graphene quantum dots possess intrinsic properties that may interact with biological systems in ways distinct from larger graphene sheets, including the ability to penetrate cellular membranes, localise within mitochondria and nuclei, and potentially interfere with DNA replication. Some researchers in this space have further speculated that GQDs could function as components within a broader Intra-Body Nano Network framework, potentially acting as optically or electromagnetically addressable nodes — a claim that remains highly contested and unverified.
It should be noted that no regulatory body has formally confirmed the presence of carbon quantum dots in approved vaccine formulations. Independent researchers argue this is precisely the problem: there is no mandatory pre-market screening protocol for quantum dot structures in injectable biologics, meaning their presence or absence has not been systematically ruled out. For a broader discussion of the graphene family allegations, see Graphene in Vaccines and Graphene Oxide.
Quantum Dots in Legitimate Biomedical Research: The MIT/Gates Foundation Precedent
Separate from the contested vaccine contamination allegations, quantum dot technology has been openly pursued as an injectable delivery and tracking mechanism in mainstream biomedical research. A widely cited example is a project developed at the Massachusetts Institute of Technology (MIT), partly funded by the Bill and Melinda Gates Foundation, which used IR Quantum Dots — near-infrared-emitting copper-based quantum dots — embedded in a dissolvable microneedle patch as an invisible subcutaneous record of vaccine administration.
Published in Science Translational Medicine in 2019, the research demonstrated that quantum dot dye patterns could be read by a suitably modified smartphone camera months or years after injection, effectively creating a covert biological record beneath the skin. The researchers framed this as a solution for vaccine record-keeping in low-resource settings where paper records are unreliable. Critics and privacy advocates have raised concerns about:
- The injection of tracking-capable nanoparticles without explicit individual awareness that a permanent sub-dermal marker is being introduced
- The potential for this technology to be incorporated into mass vaccination programmes without distinct disclosure
- The broader implications for Bodily Autonomy and Digital Identity frameworks if injectable optical markers become routine
This documented, non-controversial application of injectable quantum dot technology is significant in the context of the independent research debate: it confirms that quantum dot injection into human skin is technically feasible, biologically tolerated at the doses tested, and actively being developed by well-funded institutions. Whether this precedent supports or merely contextualises the more expansive claims about undisclosed quantum dots in COVID-19 vaccines is a matter of ongoing debate.
Dr. Pablo Campra
Dr. Pablo Campra, a Spanish materials scientist and professor at the University of Almería, published two reports in 2021–2022 using micro-Raman spectroscopy and optical microscopy on Pfizer, Moderna, AstraZeneca, and Janssen vaccine samples. His analysis claimed to identify structures consistent with graphene and reduced graphene oxide based on characteristic spectral peaks (the D, G, and 2D bands associated with sp² carbon lattices).
Campra's work was initially circulated as a preprint and was peer-reviewed under the La Quinta Columna research initiative. He acknowledged limitations including the absence of X-ray diffraction confirmation and the difficulty of definitively distinguishing graphene from other carbon-based compounds using Raman alone. His findings are discussed in detail on the Graphene in Vaccines and Graphene Oxide pages.
Dr. Ana Maria Mihalcea
Dr. Ana Maria Mihalcea, an American physician and researcher, has published extensively on what she describes as self-assembling nano-structures found in both COVID vaccine vials and the live blood of vaccinated individuals. Using darkfield microscopy — a technique that illuminates unstained samples against a dark background, making reflective or refractive particles visible — Mihalcea has documented filamentous structures, crystalline formations, and what she describes as nanotube-like assemblies.
Her work is cross-referenced with findings from other researchers including Dr. Shimon Yanowitz and raises the broader hypothesis that certain nanomaterials may be capable of self-organisation under biological conditions. These claims intersect with the Self-Assembling Nanostructures hypothesis and remain outside mainstream scientific acceptance. Mihalcea has called for formal regulatory investigation and independent replication.
Other International Researchers
Several other teams have published independent analyses:
- A group of Japanese researchers in 2022 identified metallic particles — including stainless steel-like fragments — in Moderna vaccine vials, which led Japan's Ministry of Health to suspend approximately 1.6 million doses. This is one of the few cases where a regulatory body acknowledged and acted on contamination findings.
- Italian researchers publishing in Food and Chemical Toxicology (2021) identified metallic nanoparticles including aluminium, silicon, and stainless steel microparticles in various vaccines using electron microscopy with energy-dispersive X-ray analysis (EDX), though their work covered conventional vaccines rather than specifically mRNA products.
- German pathologist findings (2021–2022) from a working group examining post-mortem tissue from individuals who died after COVID vaccination reported findings of unusual metallic aggregates in tissue samples, though causality was disputed.
Known Biological Effects of Nanoparticle Types
Peer-reviewed toxicology literature — entirely separate from vaccine debates — has established biological effects for various nanoparticle classes that may be relevant:
Graphene Oxide
Published studies in journals including ACS Nano, Particle and Fibre Toxicology, and Small have documented that graphene oxide nanoparticles can:
- Induce oxidative stress and reactive oxygen species (ROS) generation in mammalian cells
- Cause dose-dependent cytotoxicity in lung, liver, and red blood cell models
- Trigger inflammatory cytokine cascades
- Cross the blood-brain barrier in animal models
- Interact with lipid membranes, potentially disrupting cell integrity
These effects are dose, size, and surface-chemistry dependent. Proponents of the graphene-in-vaccines hypothesis argue that even trace quantities could be biologically significant given the route of administration and concentration at injection sites.
Carbon Quantum Dots: Specific Toxicological Considerations
Carbon quantum dots and graphene quantum dots occupy a distinct toxicological category from bulk graphene or graphene oxide, by virtue of their extreme size (typically 2–10 nm) and pronounced quantum effects. Emerging Nanotoxicology literature has identified several areas of concern:
- CQDs have demonstrated the ability to penetrate the nuclear envelope and interact directly with DNA in cell culture studies, raising genotoxicity questions not applicable to larger graphene structures
- Graphene quantum dots have been shown to localise in mitochondria and disrupt the mitochondrial membrane potential in hepatocyte (liver cell) models
- The photoluminescent properties of CQDs mean they may respond to specific wavelengths of electromagnetic radiation — a property that has been speculated upon in the context of external wireless signal interaction, though no peer-reviewed evidence has confirmed this in a biological context
- Surface functionalisation of CQDs strongly influences their biological fate; the same core structure can be rendered more or less toxic depending on attached chemical groups — making generalised safety assessments difficult
The Nanotoxicology page covers the broader toxicological framework for nanomaterials. Critics of the regulatory process argue that the specific toxicological profile of quantum dot-scale carbon structures has not been adequately incorporated into pre-market safety assessment for injectable products.
Metallic Nanoparticles
Iron oxide, titanium dioxide, aluminium, and silicon nanoparticles — documented in conventional vaccine preparations — have established toxicology profiles:
- Aluminium nanoparticles (used as adjuvants) have been associated with macrophagic myofasciitis, a condition documented in French research by Dr. Romain Gherardi
- Titanium dioxide nanoparticles have been classified as a possible carcinogen (Group 2B) by the International Agency for Research on Cancer (IARC) when inhaled, though injectable routes have a different risk profile
Lipid Nanoparticles Specifically
Beyond the delivery function, LNPs themselves have documented immunological effects:
- PEGylated lipids can trigger anti-PEG antibody responses, potentially causing hypersensitivity reactions on repeat exposure — a concern for booster campaigns
- Ionisable cationic lipids have been shown in animal studies to activate the NLRP3 inflammasome, an innate immune pathway linked to systemic inflammation
Methodologies Used in Independent Research
| Technique | What It Detects | Limitations |
|---|---|---|
| Optical/Darkfield Microscopy | Particle morphology, movement, aggregation | Cannot definitively identify chemical composition |
| Micro-Raman Spectroscopy | Molecular bond signatures, carbon lattice structures | Sample preparation can introduce artefacts |
| Electron Microscopy (SEM/TEM) | Nanoscale particle morphology | Expensive, requires specialist interpretation |
| EDX / EDS Analysis | Elemental composition of particles | Cannot distinguish isotopes or bonding state |
| Atomic Force Microscopy | Surface topology at atomic resolution | Requires specialised equipment and skill |
| Photoluminescence Spectroscopy | Quantum dot fluorescence emission profiles | Requires calibration against known standards; overlapping signatures possible |
The absence of independent, publicly funded replication of these findings remains a central criticism from mainstream scientists — and a frustration cited by independent researchers who argue regulatory bodies have declined to commission such work. Corona2Inspect has specifically called for formally structured replication studies using blinded samples and standardised protocols, an appeal that has not been taken up by any national medicines agency to date.
Informed Consent Implications
The doctrine of informed consent requires that individuals be provided with complete and accurate information about what is being introduced into their body. If nanomaterials beyond the declared excipients are present in vaccine preparations — whether through design, contamination, or inadequate characterisation — this raises serious questions:
- Were recipients in a position to give truly informed consent if full nanomaterial content was not disclosed?
- Do existing regulatory frameworks adequately cover novel nanomaterial characterisation for injectable products?
- Should nanomaterial safety testing — including specific screening for quantum dot structures — be a mandatory, standardised pre-market requirement for all injectable biologics?
- Does the documented development of injectable IR Quantum Dots for covert sub-dermal tracking (as in the MIT/Gates Foundation microneedle research) represent a precedent that requires explicit public consent frameworks before broader deployment?
These questions are increasingly raised in the context of Bodily Autonomy Legislation efforts in multiple jurisdictions. Researchers including Dr. Ana Maria Mihalcea and advocacy groups connected to the Targeted Individuals community argue that uninformed introduction of nanotechnology into the human body constitutes a fundamental rights violation, particularly if such materials could theoretically interact with external electromagnetic signals — a concern linking to the Intra-Body Nano Network and Biosurveillance frameworks.
See Also
- COVID Vaccines
- Lipid Nanoparticles
- Graphene Oxide
- Graphene in Vaccines
- Carbon Quantum Dot
- IR Quantum Dots
- Self-Assembling Nanostructures
- Dr. Pablo Campra
- Dr. Ana Maria Mihalcea
- La Quinta Columna
- Corona2Inspect
- Nanotechnology
- Nanotoxicology
- Bodily Autonomy
- FDA
- EMA
- Intra-Body Nano Network
- Biosurveillance
- DNA Nanotechnology
- Graphene
- Digital Identity
- Bill and Melinda Gates Foundation
References and Further Reading
- European Medicines Agency — Assessment Report, Comirnaty (BNT162b2), 2021
- Campra, P. — Micro-Raman Spectroscopic Analysis of COVID-19 Vaccines (2021, preprint)
- Gatti, A.M. & Montanari, S. — New Quality-Control Investigations on Vaccines: Micro- and Nanocontamination, International Journal of Vaccines and Vaccination (2017)
- Gherardi, R.K. et al. — Macrophagic myofasciitis: characterization and pathophysiology, Lupus (2012)
- Nakagawa, Y. et al. — Japanese Ministry of Health contamination report on Moderna batches (2021)
- McHugh, K.J. et al. — Biocompatible near-infrared quantum dots delivered to the skin by microneedle patches record vaccination, Science Translational Medicine (2019)
- Yao, Y. et al. — Graphene quantum dots: toxicity and biocompatibility studies, ACS Nano (2020, review)
- La Quinta Columna / Corona2Inspect — Technical Reports on Graphene Quantum Dot Structures in COVID-19 Vaccine Samples (2021–2022, preprint series)
